AgomAb Therapeutics
ActiveSummary
AgomAb Therapeutics has been active since 2017 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €244.1m and a net result of -€9.6m. Equity is growing by about 109% per year across the filed financial years. Its solvency ranks better than 95% of 886 sector peers (NACE 71, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
Group and network
Holdings and subsidiaries
2 holdingsHoldings 2
Source for every holding own accounts 2025
- Agomab Spain SLUESsubsidiaryEquity -€109.0mResult -€43.1m100%
- Agomab US Inc.USsubsidiaryEquity -USD 237,106Result -USD 53,760100%
According to the 2025 annual accounts of AgomAb Therapeutics and those of the other companies, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.